AveXis SMA gene therapy advances toward pivotal trial – FierceBiotech
FierceBiotech |
AveXis SMA gene therapy advances toward pivotal trial
FierceBiotech AveXis has posted top-line data from a phase 1 trial of its gene therapy against spinal muscular atrophy (SMA). All 15 patients were event-free at 13.6 months of age, a significant improvement over the natural history of the disease. The phase 1 gave … AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Results of Operations and Financial Condition AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 … Edited Transcript of AVXS earnings conference call or presentation 16-Mar-17 8:30pm GMT |
